


## Adding radiation to systemic therapy extends overall survival for patients with advanced liver cancer

October 24 2022





Credit: Pixabay/CC0 Public Domain

Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a randomized phase III clinical trial shows.

Findings indicate that <u>radiation therapy</u> should be a standard treatment option for patients with liver cancer who are ineligible for resection and other standard local-regional therapies. Results of the NRG Oncology/RTOG 1112 trial (NCT01730937) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

"Adding <u>radiation</u> therapy to <u>systemic therapy</u> delayed tumor progression and lengthened survival, without an increase in side effects. In all regards, the combination of radiation therapy and <u>sorafenib</u> appears more effective than the drug on its own," said Laura A. Dawson, MD, FASTRO, lead author of the study, as well as a professor of <u>radiation oncology</u> at the University of Toronto and a practicing radiation oncologist at the Princess Margaret Cancer Center/University Health Network in Toronto.

Liver cancers are among the most diagnosed cancers and the third leading cause of cancer death worldwide. Incidence rates of hepatocellular carcinoma (HCC), the most common type of liver cancer, in the United States have more than tripled since 1980, and <u>mortality</u> <u>rates</u> have also risen despite the growing availability of screening and improved treatments for the diseases that increase the risk of liver



cancer.

Systemic therapy is the standard of care for patients with HCC who are not eligible for surgical resection or other invasive therapies, but a growing number of studies suggest a benefit of radiation therapy for these patients. The trial led by Dr. Dawson is the first randomized North American study focused specifically on the role of radiation therapy for these patients.

Participants in the trial included 193 patients (177 eligible for analyses) with new or recurrent advanced HCC who were ineligible for <u>surgical</u> resection or other local or regional standard therapies due to underlying clinical factors or because their cancer had returned after standard therapy. Most patients had invasion of their cancer into the hepatic vasculature (a poor prognostic factor), and a small number had metastases outside of the <u>liver</u>. The median age was 66 years (range 27-84).

Trial participants were randomized at 23 sites in the U.S. and Canada to receive either sorafenib alone or stereotactic body radiation therapy (SBRT) followed by sorafenib. Sorafenib was the standard systemic therapy when the study began. SBRT was delivered in five fractions over five to ten days, with total doses between 27.5 and 50Gy, individualized to each patient based on clinical factors.

Overall survival was longer for patients who received a combination of SBRT and sorafenib, compared to those on sorafenib alone (15.8 vs. 12.3 months; one-sided p = 0.055). The difference was statistically significant after controlling for clinical prognostic factors such as performance status and the degree of vascular invasion (p=0.042).

"It was a little ambitious to design a study with overall survival as the primary endpoint, but when we designed the trial, there were limited



systemic therapies available for these patients, and we had strong signals from earlier research that adding SBRT to sorafenib should improve tumor control and lead to improved survival," said Dr. Dawson.

"We can now say without hesitation that radiation therapy is an <u>effective</u> <u>treatment</u> for patients with unresectable <u>liver cancer</u>. Outcomes were better for patients treated with SBRT, despite the planned delay in starting sorafenib."

Progression-free survival was improved with the addition of SBRT, from 5.5 months with sorafenib alone to 9.2 months with the combination therapy (HR = 0.92, p

Citation: Adding radiation to systemic therapy extends overall survival for patients with advanced liver cancer (2022, October 24) retrieved 24 April 2024 from <u>https://medicalxpress.com/news/2022-10-adding-therapy-survival-patients-advanced.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.